SARS-CoV-2 variants and ending the COVID-19 pandemic
- 11 February 2021
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 397 (10278), 952-954
- https://doi.org/10.1016/s0140-6736(21)00370-6
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human seraScience, 2021
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variantsNature, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaThe Lancet, 2021
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)SSRN Electronic Journal, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- How COVID vaccines are being divvied up around the worldNature, 2020
- Understanding COVID-19 vaccine efficacyScience, 2020
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacyScience, 2020